Zobrazeno 1 - 4
of 4
pro vyhledávání: '"A. E. Barybin"'
Autor:
N. Yu. Mironov, Yu. A. Yuricheva, V. V. Vlodzyanovskiy, S. F. Sokolov, Kh. M. Dzaurova, S. P. Golitsyn, Yu. V. Shubik, M. V. Berman, M. M. Medvedev, A. E. Rivin, D. S. Parkhomchuk, A. E. Barybin, D. А. Balandin, R. E. Batalov, D. V. Terekhov, I. V. Evstifeev, I. R. Kildeev, O. V. Pyataeva, S. A. Zenin
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 17, Iss 5, Pp 668-673 (2021)
Aim. We aimed to assess safety and effectiveness of class III antiarrhythmic drug Refralon for conversion of atrial fibrillation (AFib) and flutter (AFl) in post-registration trial and to compare data of primary center (National medical research cent
Externí odkaz:
https://doaj.org/article/fda3bc3bcec0409e89ef6af250af93a3
Autor:
N. Yu. Mironov, Yu. A. Yuricheva, V. V. Vlodzyanovskiy, S. F. Sokolov, Kh. M. Dzaurova, S. P. Golitsyn, Yu. V. Shubik, M. V. Berman, M. M. Medvedev, A. E. Rivin, D. S. Parkhomchuk, A. E. Barybin, D. А. Balandin, R. E. Batalov, D. S. Terekhov, I. V. Evstifeev, I. R. Kildeev, O. V. Pyataeva, S. A. Zenin
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 17, Iss 2, Pp 193-199 (2021)
Aim. We aimed to assess safety and effectiveness of class III antiarrhythmic drug Refralon for conversion of atrial fibrillation (AFib) and flutter (AFl) in post-registration trial and to compare data of primary center (National medical research cent
Externí odkaz:
https://doaj.org/article/0f377f87549f4a628c7889891fa7039f
Autor:
A. E. Rivin, M. V. Berman, O. V. Pyataeva, V. V. Vlodzyanovskiy, Yu. A. Yuricheva, I. V. Evstifeev, Sergey P. Golitsyn, Kh. M. Dzaurova, S. A. Zenin, M. M. Medvedev, D. S. Parkhomchuk, S. F. Sokolov, Yu. V. Shubik, R. E. Batalov, D. V. Terekhov, D. А. Balandin, A. E. Barybin, N. Yu. Mironov, I. R. Kildeev
Publikováno v:
Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 17, Iss 5, Pp 668-673 (2021)
Aim.We aimed to assess safety and effectiveness of class III antiarrhythmic drug Refralon for conversion of atrial fibrillation (AFib) and flutter (AFl) in post-registration trial and to compare data of primary center (National medical research cente
Autor:
O. V. Pyataeva, V. V. Vlodzyanovskiy, Yu. A. Yuricheva, I. V. Evstifeev, D. А. Balandin, A. E. Rivin, I. R. Kildeev, D. S. Terekhov, A. E. Barybin, M. V. Berman, S. F. Sokolov, N. Yu. Mironov, D. S. Parkhomchuk, Sergey P. Golitsyn, R. E. Batalov, Yu. V. Shubik, S. A. Zenin, M. M. Medvedev, Kh. M. Dzaurova
Publikováno v:
Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 17, Iss 2, Pp 193-199 (2021)
Aim.We aimed to assess safety and effectiveness of class III antiarrhythmic drug Refralon for conversion of atrial fibrillation (AFib) and flutter (AFl) in post-registration trial and to compare data of primary center (National medical research cente